COMT inhibition in the treatment of Parkinson's disease

Journal of Neurology, Supplement

Volumn 245, Issue 3, 1998, Pages

  Ruottinen, H M ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Catechol O methyltransferase inhibition; End of dose fluctuations; Entacapone; Parkinson's disease; Tolcapone

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; LIVER ENZYME; TOLCAPONE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; APPETITE DISORDER; CONFERENCE PAPER; CONFUSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DYSKINESIA; DYSPEPSIA; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EPIGASTRIC PAIN; ERYTHROCYTE; FATIGUE; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; VERTIGO; VOMITING;

BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; HUMANS; LEVODOPA; NITROPHENOLS; PARKINSON DISEASE;

EID: 0031708101     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (2)

1. Agid Y, Destée A, Durif F, Montastruc J-L, Pollak P, and the French Tolcapone Study Group (1997) Tolcapone, bromocriptine and Parkinson's disease. Lancet 350:712-713
2. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G, and the study investigators (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the "vvearing-off ' phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63:421-428